Company Performance Metrics
- Michael Brownstein: Sr. VP Drug Development
- Neal G. Simon: CEO
Azevan Pharmaceuticals, Inc., a clinical stage, small molecule drug development company, develops therapeutics to treat disorders of stress, mood, and behavior. The company specializes in clinical compounds that selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of major depression,
intermittent explosive disorder, impulse control/anger disorders, and post-traumatic stress disorder (PTSD). Its products include SRX251 and SRX246 CNS-penetrating V1a receptor antagonists that are orally bioavailable. The company's SRX246 and SRX251 are developed for stress-related CNS disorders, including depression, PTSD, and intermittent explosive disorders. Azevan Pharmaceuticals, Inc. was formerly known as Serenix Pharmaceuticals, LLC and changed its name to Azevan Pharmaceuticals, Inc. in January 2002. The company was founded in 1999 and is based in Bethlehem, Pennsylvania.
